Redicure, opening up the future of medical innovation.

Redicure was founded in 2021 as a leading company developing
AI-based digital X-ray solutions for the treatment of degenerative neurological diseases such as Alzheimer's and Parkinson's.
Currently, based on the results of early exploratory clinical studies on the therapeutic effects of low-dose X-ray,
we are developing a low-dose X-ray treatment system, HeLaXON.
We are securing scientific evidence to prove the multi-mechanism of low-dose X-ray and the effectiveness of low-energy,
pulsed beams, and expanding our research for advancement.
We are developing a digital X-ray-only medical system with personalized treatment software
by combining treatment methods based on research results and
AI technology, suggesting a new paradigm for non-pharmaceutical degenerative neurological disease treatment.

Redicure will build a digital X-ray treatment ecosystem to provide more efficient and
safer treatment to patients with degenerative neurological diseases such as Alzheimer's disease,
and will further establish itself as a leading company in the diagnosis and treatment of degenerative neurological diseases,
and aim to improve the quality of life of patients and their guardians.

We dream of a bigger leap forward based on our past experiences and have the passion to prepare for the future.
We want to create a brighter future based on continuous innovation and
social responsibility.